BioSante Pharmaceuticals is a development stage biotech company focusing on drugs for sexual health and oncology. TooNiceStocks research discovered the recent collapse in the company’s stock on December 14, 2011 from the day’s high of 2.60 to a low of 0.38 in after hours trading, have left many investors asking, "so what's next for BioSante?" Since then, BioSante has slowly recovered somewhat, the stock is still trading at a much-reduced range of $.50, a substantial discount of roughly $52 million market cap compared to about $286 million before the news. However with one drug approved and another facing a regulatory decision in the form of a PDUFA on February 14th, 2012, smallcap investors are already gambling.
Aeterna Zentaris is a late stage oncology drug development company with numerous upcoming milestones and catalyst. TooNiceStocks research found their pipeline includes Perifosine, Solorel, and AEZS-108, each with multiple indications. With ASCO coming in June TooNiceStocks anticipates AEZS-108 Phase 1/2 data on refractory bladder and prostate or Perifosine Phase III X-PECT interim data will be released.
Advaxis Incorporated, a development stage biotechnology company, is poised for a major advancement if their Phase II cervical cancer vaccine data reflects the same optimistic survival data from prior Phase I data. Advaxis initiated two Phase II trials, one aboard and another in the United States. The India trial began December 2010, accordingly the interim data should be released by the summer of 2011.
TooNiceStocks research has found that Talon Therapeutics is poised for major breakthroughs with their patented drug Marqibo. Marqibo is a nanoparticle encapsulated cancer therapeutic. This unique technology enhances efficacy while reducing toxicity.
TooNiceStocks research has uncovered a near term catalyst for Acura Pharmaceuticals, Inc. On February 14th, 2011, the FDA accepted the NDA for Acura’s lead product, Acurox. The drug was granted a priority review with a PDUFA (Prescription Drug User Fee Act) date of June 17th, 2011.
TooNiceStocks presents its research analysis on IntelGenx Corporation and its lead product CPI-300 with indications for MDD, major depressive disorder. Since its complete response letter, from the FDA in February of 2010 for CPI-300...
Genta Incorporated an oncology drug development and commercialization company will release the long awaited AGENDA’s overall survival data during early Q2 2011...
Neoprobe Corporation is the only company to optimize radiotracers and gamma detection hardware concurrently, providing tremendous growth opportunity. Neoprobe have been making remarkable strides within their financial and pipeline. In fiscal year 2010, reported revenue increased 12% and...
TooNiceStocks research has unearthed a near-term catalyst in CorMedix Inc. in the form of interim data to be revealed in its phase II trial for its lead product, CRMD001 Deferiprone...
TooNiceStocks believes with Corcept Therapeutics planning to submit the NDA at the end of first quarter and present detailed Phase III data at the Endocrine Society Annual Meeting...
